Literature DB >> 1646845

A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex.

R Q Hintzen1, R de Jong, C E Hack, M Chamuleau, E F de Vries, I J ten Berge, J Borst, R A van Lier.   

Abstract

The human T cell Ag CD27 belongs to a recently defined family of cell surface receptors, including the nerve growth factor receptor, two distinct tumor necrosis factor receptors, and the B cell specific molecule CD40. On resting T cells, CD27 is a transmembrane homodimer with subunits of 50 to 55 kDa (p55). T cell activation via the TCR/CD3 complex causes a strong enhancement of p55 expression. Concomitantly, an alternative form of the CD27 molecule with a molecular mass of 28 to 32 kDa (p32) appears at the cell surface. With the use of ELISA, we here show that a soluble form of CD27 (sCD27) can be detected in the supernatant of T cells activated with anti-CD3 or combinations of anti-CD2 mAb. Moreover, sCD27 is found in both serum and urine from healthy donors. sCD27, purified from either culture supernatant or urine, has a molecular mass of 28 to 32 kDa and is, according to peptide mapping, structurally homologous to the p55 membrane form of CD27. Quantification of sCD27 levels may be used as a marker for T lymphocyte activation in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1646845

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  The metalloproteinase inhibitor GI5402 inhibits endotoxin-induced soluble CD27 and CD16 release in healthy humans.

Authors:  P E Dekkers; T ten Hove; F N Lauw; H R Koene; P Lumley; S J van Deventer; T van der Poll
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

2.  CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study.

Authors:  A Stronkhorst; S Radema; S L Yong; H Bijl; I J ten Berge; G N Tytgat; S J van Deventer
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

3.  Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy.

Authors:  Robert C Kalayjian; Rhoderick N Machekano; Nesrine Rizk; Gregory K Robbins; Rajesh T Gandhi; Benigno A Rodriguez; Richard B Pollard; Michael M Lederman; Alan Landay
Journal:  J Infect Dis       Date:  2010-06-15       Impact factor: 5.226

4.  CD70 Activation Decreases Pulmonary Fibroblast Production of Extracellular Matrix Proteins.

Authors:  Thi K Tran-Nguyen; Jianmin Xue; Carol Feghali-Bostwick; Frank C Sciurba; Daniel J Kass; Steven R Duncan
Journal:  Am J Respir Cell Mol Biol       Date:  2020-08       Impact factor: 6.914

5.  Quantitation of soluble CD27, a T-cell activation antigen, and soluble interleukin-2 receptor in serum from patients with psoriasis.

Authors:  M A de Rie; F Hamerlinck; R Q Hintzen; J D Bos; R A van Lier
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

6.  Expression of CD27 on peripheral CD4+ T-lymphocytes correlates with the development of severe acute graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  Hitoshi Yoshida; Tetsuo Maeda; Jun Ishikawa; Shinya Inoue; Hitomi Matsunaga; Satoru Kosugi; Masamichi Shiraga; Kenji Oritani; Yuzuru Kanakura; Yoshiaki Tomiyama
Journal:  Int J Hematol       Date:  2006-11       Impact factor: 2.490

7.  Blockade of protease-activated receptors on T cells correlates with altered proteolysis of CD27 by gingipains of Porphyromonas gingivalis.

Authors:  L W P Yun; A A Decarlo; N Hunter
Journal:  Clin Exp Immunol       Date:  2007-11       Impact factor: 4.330

8.  Late signals from CD27 prevent Fas-dependent apoptosis of primary CD8+ T cells.

Authors:  Douglas V Dolfi; Alina C Boesteanu; Constantinos Petrovas; Dong Xia; Eric A Butz; Peter D Katsikis
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

9.  Therapeutic granulocyte and monocyte apheresis (GMA) for treatment refractory sarcoidosis: a pilot study of clinical effects and possible mechanisms of action.

Authors:  H H Olsen; V Muratov; K Cederlund; J Lundahl; A Eklund; J Grunewald
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

10.  Serum levels of soluble forms of T cell activation antigens CD27 and CD25 in systemic lupus erythematosus in relation with lymphocytes count and disease course.

Authors:  A J Swaak; R Q Hintzen; V Huysen; H G van den Brink; J T Smeenk
Journal:  Clin Rheumatol       Date:  1995-05       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.